Yelin Lapidot Holdings Management Ltd. Lowers Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Yelin Lapidot Holdings Management Ltd. cut its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 10.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 354,704 shares of the company’s stock after selling 40,800 shares during the quarter. Teva Pharmaceutical Industries accounts for about 2.2% of Yelin Lapidot Holdings Management Ltd.’s holdings, making the stock its 13th biggest holding. Yelin Lapidot Holdings Management Ltd.’s holdings in Teva Pharmaceutical Industries were worth $10,684,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. grew its position in Teva Pharmaceutical Industries by 19.2% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after acquiring an additional 7,255,083 shares in the last quarter. Menora Mivtachim Holdings LTD. lifted its stake in Teva Pharmaceutical Industries by 1.1% during the third quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock worth $786,190,000 after purchasing an additional 427,000 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its stake in Teva Pharmaceutical Industries by 18.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 14.8% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock worth $1,167,323,000 after purchasing an additional 4,820,000 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $1,098,060,000. Institutional investors own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 21,258 shares of the company’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the transaction, the executive vice president directly owned 63,647 shares of the company’s stock, valued at approximately $2,247,375.57. This represents a 25.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Mark Sabag sold 144,180 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the transaction, the insider directly owned 80,760 shares of the company’s stock, valued at approximately $2,825,792.40. This trade represents a 64.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 465,931 shares of company stock valued at $16,332,989. 0.54% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on TEVA shares. Barclays raised their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Truist Financial upped their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $41.78.

Teva Pharmaceutical Industries Trading Up 0.1%

NYSE TEVA opened at $33.24 on Monday. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The stock has a 50-day moving average of $33.73 and a 200-day moving average of $32.42. The firm has a market cap of $38.22 billion, a PE ratio of 24.99, a price-to-earnings-growth ratio of 4.06 and a beta of 0.84.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The business had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.